Medpace Holdings (MEDP), Mettler-Toledo International (MTD), and Thermo Fisher Scientific (TMO) represent distinct yet related segments within the life sciences ecosystem. MEDP provides outsourced clinical research services, MTD specializes in precision weighing and analytical instruments, and TMO offers a broad portfolio of scientific instrumentation, reagents, and diagnostics. This comparison examines their recent stock behavior, business positioning, and relative performance in the current market environment. Institutional investors, sector-focused traders, and portfolio managers seeking exposure to healthcare innovation and laboratory demand may find the analysis relevant for assessing diversification and momentum opportunities.
Medpace Holdings (MEDP) operates as a contract research organization (CRO) focused on clinical trial management for pharmaceutical, biotechnology, and medical device clients. In recent market activity, the stock has shown strength following second-quarter 2026 results that exceeded expectations, with revenue rising 17.2% year-over-year to $707.3 million and earnings per share (EPS) of $4.25 beating consensus. The company raised its full-year 2026 revenue guidance to a range of $2.805 billion to $2.885 billion. Shares have traded in the $580–$620 range amid multiple analyst price target upgrades, though some insider selling has occurred. Sentiment has been supported by record bookings and backlog expansion, particularly in metabolic and oncology areas, contributing to a market capitalization near $17 billion.
Mettler-Toledo International (MTD) provides precision instruments and solutions for laboratory, industrial, and product inspection applications. Recent market activity reflects a positive response to second-quarter 2026 earnings that surpassed estimates, fueled by sales growth in China and emerging markets. The company raised its full-year outlook, and in August 2026, Zacks upgraded the stock to a Buy rating. Shares have hovered around $1,390, with a market capitalization exceeding $30 billion implied by trading levels. Performance has been influenced by productivity initiatives and pricing realization, supporting adjusted EPS growth while broader industrial demand shows signs of stabilization.
Thermo Fisher Scientific (TMO) delivers scientific instrumentation, consumables, and services across research, diagnostics, and bioprocessing markets. In recent market activity, the company reported second-quarter 2026 organic revenue growth of 5%, the fastest since 2021, leading to an upward revision in full-year guidance. Revenue reached $11.99 billion, with adjusted EPS of $6.03. Shares have traded near $650, supporting a market capitalization of approximately $241 billion. Sentiment has benefited from improving customer activity in pharma and biotech, alongside capital returns through $1 billion in share repurchases during the quarter and ongoing portfolio optimization.
Tickeron’s Trending AI Robots page highlights select AI trading bots from a library of hundreds that execute strategies across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions—based on backtested performance, risk metrics, and adaptability—earn placement in this curated section. Available bots span diverse trading styles, strategies, timeframes, and ticker sets, with historical win rates, profit factors, and drawdown statistics varying widely to suit different risk tolerances. This resource allows traders to review transparent performance data before considering bot deployment. Explore the full selection on the Trending AI Robots page for detailed statistics.
Medpace Holdings (MEDP), Mettler-Toledo International (MTD), and Thermo Fisher Scientific (TMO) differ in scale and focus: MEDP emphasizes clinical services with high growth sensitivity to biopharma funding cycles, MTD centers on precision hardware with exposure to industrial and lab capital spending, and TMO combines instrumentation with consumables for greater revenue stability. Recent momentum favors MEDP following its earnings-driven rally, while MTD and TMO have posted more measured advances tied to regional demand recovery. Risk factors include client concentration for MEDP, cyclical instrument purchases for MTD, and broader macroeconomic pressures on lab budgets for TMO. Valuation multiples reflect growth differentials, with MEDP commanding a premium, whereas TMO offers scale-driven resilience and MTD provides niche leadership in measurement technology. Sector exposure overlaps in life sciences, yet trade-offs emerge in volatility profiles and catalyst responsiveness.
Based on observable trend consistency, earnings momentum, and relative positioning, Tickeron’s AI would currently assign a probabilistic edge to Medpace Holdings (MEDP). The stock’s post-earnings trajectory, raised guidance, and backlog indicators suggest stronger near-term visibility compared to peers. Mettler-Toledo International (MTD) and Thermo Fisher Scientific (TMO) demonstrate solid stability and execution but exhibit comparatively tempered recent acceleration. This assessment draws from verifiable performance patterns rather than forecasts.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MEDP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 31 cases where MEDP's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 58 cases where MEDP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on MEDP as a result. In 71 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for MEDP just turned positive on October 15, 2026. Looking at past instances where MEDP's MACD turned positive, the stock continued to rise in 36 of 52 cases over the following month. The odds of a continued upward trend are 69%.
MEDP moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDP advanced for three days, in 238 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 197 of 260 cases where MEDP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 21 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 40 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. MEDP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (39.683) is normal, around the industry mean (72.578). P/E Ratio (36.187) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (2.929) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (6.390) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Moving Average Convergence Divergence (MACD) for MTD turned positive on September 17, 2026. Looking at past instances where MTD's MACD turned positive, the stock continued to rise in 31 of 48 cases over the following month. The odds of a continued upward trend are 65%.
The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on MTD as a result. In 48 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
MTD moved above its 50-day moving average on September 16, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MTD crossed bullishly above the 50-day moving average on September 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 41%.
Following a +2.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where MTD advanced for three days, in 193 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 136 of 230 cases where MTD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MTD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
MTD broke above its upper Bollinger Band on October 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is 3 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. MTD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 89 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MTD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MTD's P/B Ratio (2500.000) is very high in comparison to the industry average of (72.578). P/E Ratio (34.835) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (2.869) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (6.798) is also within normal values, averaging (9.775).
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TMO advanced for three days, in 196 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 33 of 55 cases where TMO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on TMO as a result. In 54 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 147 of 248 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.
The 10-day RSI Indicator for TMO moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 25 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 66%.
The Moving Average Convergence Divergence Histogram (MACD) for TMO turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 30 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
TMO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.762) is normal, around the industry mean (72.578). P/E Ratio (36.523) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.001) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 73 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
MEDP | MTD | TMO | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 42 | 41 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 99 Overvalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 21 | 89 | 73 | |
SMR RATING 1..100 | 11 | 3 | 60 | |
PRICE GROWTH RATING 1..100 | 41 | 8 | 10 | |
P/E GROWTH RATING 1..100 | 40 | 27 | 15 | |
SEASONALITY SCORE 1..100 | 90 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (13) in the Medical Specialties industry is somewhat better than the same rating for MEDP (72) in the Miscellaneous Commercial Services industry, and is significantly better than the same rating for MTD (99) in the Medical Specialties industry. This means that TMO's stock grew somewhat faster than MEDP’s and significantly faster than MTD’s over the last 12 months.
MEDP's Profit vs Risk Rating (21) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for TMO (73) in the Medical Specialties industry, and is significantly better than the same rating for MTD (89) in the Medical Specialties industry. This means that MEDP's stock grew somewhat faster than TMO’s and significantly faster than MTD’s over the last 12 months.
MTD's SMR Rating (3) in the Medical Specialties industry is in the same range as MEDP (11) in the Miscellaneous Commercial Services industry, and is somewhat better than the same rating for TMO (60) in the Medical Specialties industry. This means that MTD's stock grew similarly to MEDP’s and somewhat faster than TMO’s over the last 12 months.
MTD's Price Growth Rating (8) in the Medical Specialties industry is in the same range as TMO (10) in the Medical Specialties industry, and is somewhat better than the same rating for MEDP (41) in the Miscellaneous Commercial Services industry. This means that MTD's stock grew similarly to TMO’s and somewhat faster than MEDP’s over the last 12 months.
TMO's P/E Growth Rating (15) in the Medical Specialties industry is in the same range as MTD (27) in the Medical Specialties industry, and is in the same range as MEDP (40) in the Miscellaneous Commercial Services industry. This means that TMO's stock grew similarly to MTD’s and similarly to MEDP’s over the last 12 months.
| MEDP | MTD | TMO | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 86% | 1 day ago 66% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 73% | 1 day ago 60% |
| Momentum ODDS (%) | 1 day ago 72% | 1 day ago 59% | 1 day ago 61% |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 65% | 1 day ago 71% |
| TrendWeek ODDS (%) | 1 day ago 75% | 1 day ago 61% | 1 day ago 62% |
| TrendMonth ODDS (%) | 1 day ago 77% | 1 day ago 60% | 1 day ago 62% |
| Advances ODDS (%) | 1 day ago 75% | 1 day ago 61% | 1 day ago 63% |
| Declines ODDS (%) | 18 days ago 63% | 15 days ago 66% | 15 days ago 62% |
| BollingerBands ODDS (%) | 1 day ago 87% | 1 day ago 81% | 1 day ago 63% |
| Aroon ODDS (%) | 1 day ago 76% | 1 day ago 59% | 1 day ago 59% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MEDP’s FA Score shows that 2 FA rating(s) are green while MTD’s FA Score has 3 green FA rating(s), and TMO’s FA Score reflects 3 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MEDP’s TA Score shows that 7 TA indicator(s) are bullish while MTD’s TA Score has 6 bullish TA indicator(s), and TMO’s TA Score reflects 4 bullish TA indicator(s).
MEDP (@Medical Specialties) experienced а +4.30% price change this week, while MTD (@Medical Specialties) price change was +7.16% , and TMO (@Medical Specialties) price fluctuated +6.83% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.21%. For the same industry, the average monthly price growth was +0.79%, and the average quarterly price growth was +37.83%.
MEDP is expected to report earnings on Oct 21, 2026.
MTD is expected to report earnings on Nov 05, 2026.
TMO is expected to report earnings on Oct 21, 2026.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
A.I.dvisor indicates that over the last year, MEDP has been loosely correlated with TMO. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if MEDP jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To MEDP | 1D Price Change % | ||
|---|---|---|---|---|
| MEDP | 100% | +1.94% | ||
| TMO - MEDP | 61% Loosely correlated | +3.46% | ||
| CRL - MEDP | 57% Loosely correlated | +1.40% | ||
| A - MEDP | 44% Loosely correlated | +0.89% | ||
| RVTY - MEDP | 44% Loosely correlated | +1.70% | ||
| BRKR - MEDP | 43% Loosely correlated | +1.69% | ||
More | ||||
A.I.dvisor indicates that over the last year, MTD has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if MTD jumps, then A could also see price increases.
| Ticker / NAME | Correlation To MTD | 1D Price Change % | ||
|---|---|---|---|---|
| MTD | 100% | +1.85% | ||
| A - MTD | 68% Closely correlated | +0.89% | ||
| BRKR - MTD | 67% Closely correlated | +1.69% | ||
| TMO - MTD | 62% Loosely correlated | +3.46% | ||
| AZTA - MTD | 61% Loosely correlated | -1.78% | ||
| RGEN - MTD | 58% Loosely correlated | +3.35% | ||
More | ||||
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.
| Ticker / NAME | Correlation To TMO | 1D Price Change % | ||
|---|---|---|---|---|
| TMO | 100% | +3.46% | ||
| A - TMO | 74% Closely correlated | +0.89% | ||
| DHR - TMO | 71% Closely correlated | +3.03% | ||
| RVTY - TMO | 70% Closely correlated | +1.70% | ||
| IQV - TMO | 68% Closely correlated | +3.45% | ||
| BRKR - TMO | 67% Closely correlated | +1.69% | ||
More | ||||